ArticleActa orthopaedica2026
Pathological fracture as initial manifestation of malignancy and survival based on diagnoses: a register-based cohort study from the Swedish Fracture Register and the Swedish Cancer Register.
Article in Acta orthopaedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposePathological fracture as the initial manifestation of malignancy is a clinical challenge requiring rapid treatment despite limited prognostic information. We aimed to describe definitive diagnoses and survival in patients presenting with a pathological fracture as initial manifestation of malignancy.
methodsWe performed a nationwide register-based cohort study using the Swedish Fracture Register (SFR) and Swedish Cancer Register (SCR), 2014-2023. We included patients with a pathological fracture classified as unknown in the SFR at treatment. Survival was analyzed using Kaplan-Meier and Cox regression.
resultsWe included 319 patients with a pathological fracture. Median age was 75 years (17-100), 50% men. A definitive tumor diagnosis was established in 215 patients (67%), most commonly a hematogenous malignancy. Age was associated with mortality (HR 1.03, 95% confidence interval [CI] 1.01-1.04). Compared with hematogenous malignancies, mortality was higher for bone (HR 2.9, CI 1.2-7.2), breast (HR 2.5, CI 1.2-5.1), kidney (HR 3.3, CI 1.7-6.5), lung (HR 6.3, CI 3.7-10.5), unknown (HR 8.1, CI 4.2-15.5), other (HR 10.3, CI 5.6-19.0), and gastrointestinal malignancies (HR 10.3, CI 4.5-23.7), and for patients without SCR registration (HR 19.7, CI 11.7-33.2). Prostate cancer, sex, fracture site, and treatment were not associated with increased mortality.
conclusionHematogenous and lung malignancies were the most common in pathological fracture as initial manifestation of malignancy. Survival was short and varied substantially by tumor type. Age and primary tumor site were prognostic factors, emphasizing the importance of comprehensive diagnostic work-up to guide acute treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.